BioSpace News Archive

In the study published October 7th in Science Translational Medicine, Dr. Weiss et al shared that immunocytokines delivered systemically were effective in mice models and a pilot human trial.

10X Genomics just agreed to acquire ReadCoor, Inc., an innovator in the nascent field of in situ technology. The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology.

The investigational drug, ARO-AAT, is a potential first-in-class treatment that reduces the generation of mutant alpha-1 antitrypsin protein (Z-AAT), the primary contributor to liver disease progression in patients with AATLD.

Teleflex Incorporated, has been recognized as part of Forbes’ annual list of America’s Best-In-State Employers 2020.

Pfizer Inc. and OPKO Health Inc. announced that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth hormone deficiency, met its primary endpoint of improved treatment burden compared to GENOTROPIN® for injection administered once-daily.

Applied Genetic Technologies Corporation, a biotechnology company focused on developing adeno-associated virus based gene therapies for the treatment of rare inherited diseases, announced that management will participate in the following virtual conferences:

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, confirmed that it will report third quarter 2020 financial results on Thursday, October 29, 2020 after the market closes.

Company Also Presenting Phase 1/1b Results for MK-8507, a New Investigational Once-Weekly Oral HIV Agent; Company Advances MK-8507 to Phase 2

- Galaxy Medical, a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, today announced that the first patients in the ECLIPSE-AF study were successfully treated with the proprietary Centauri ™ System by Dr. Ante Anić in Split, Croatia. This multicenter trial is designed to assess the s

Three Oaks Hospice has joined Hospice Pharmacy Solutions’ Tru360™ program and its national network of community-based pharmacies to improve financial performance, reduce staff workload, and increase patient outcomes.